India Globalization Capital, Inc. (NYSE American:IGC) today announces that it has signed a Joint Development and Services Agreement with the prestigious Parkinson’s Institute and Clinical Center of Sunnyvale, California.
The Parkinson’s Institute and Clinical Center will work with IGC in identifying new clinical end points for Parkinson’s disease and movement disorders that could be used to determine if natural products can help with the debilitating symptoms in Parkinson’s patients. The Parkinson’s Institute and Clinical Center will assist in designing trials and creating protocols including a schedule of assessment, exclusion criteria, and registration with the National Institute of Health (NIH) and other agencies as required using IGC’s cannabis extracted products. Dr. Carrolee Barlow, CEO, Parkinson’s Institute and Clinical Center, a renowned expert in neuroscience & neurodegeneration, will be the lead on these initiatives.
From the desk of Executives
“We believe that cannabis-based compounds can become part of the solution to treat the symptoms of challenging and progressive medical conditions such as Parkinson’s disease and movement disorders. Dr. Barlow and the Parkinson’s Institute and Clinical Center are highly respected in the field and we look forward to working together to bring cannabis-based options to those afflicted by this difficult diagnosis,” stated Ram Mukunda, CEO of IGC.
“We feel very fortunate to collaborate with IGC in a rigorous research approach to determine whether holistic cannabis products can alleviate the symptoms of Parkinson’s and movement disorders,” says Dr. Carrolee Barlow, CEO, Parkinson’s Institute and Clinical Center. “This is an opportunity for the Parkinson’s Institute and Clinical Center to participate in this scientific clinical study to help Parkinson’s patients worldwide.”
About Parkinson’s Institute and Clinical Center
The Parkinson’s Institute and Clinical Center is at the forefront of patient care and therapy development. We are the nation’s only Institute that provides patient care, basic science research, and clinical research in one integrated model. Our unique freestanding organization directly connects research to patient care – from the “bench to bedside.” For 30 years, our team of epidemiologists, physicians, scientists, and therapists, have been at the forefront of every clinical and scientific discovery in the field of Parkinson’s research.
Since our inception, patients have come from 38 states and many foreign countries for their care. We have managed more than 135 clinical research trials, medically evaluating more than 95 different drugs and therapies for Parkinson’s. The result: our Institute has been directly involved in bringing every Parkinson’s drug currently available to the market. The Institute is at the forefront of discovering and developing the latest, most innovative treatments and therapies for people living with Parkinson’s. For more information visit www.thepi.org.
Carolee Barlow, MD, Ph.D.Parkinson’s Institute and Clinical Center – CEO
Carrolee Barlow, MD, Ph.D. is a renowned expert in neuroscience and neurodegeneration. She is the Parkinson’s Institute and Clinical Center’s Chief Executive Officer (CEO). She joined the Parkinson’s Institute in February 2014 and is one of only two CEO’s who has run the organization since it was founded in 1988 by Dr. J. Langston.
Dr. Barlow’s career has focused on clinical care, laboratory, and clinical research, academia and industry. She is the founder and former Chief Scientific Officer and Chief Medical Officer of BrainCells, Inc. in San Diego, California, a biotechnology company focused on the discovery and development of small molecules that stimulate adult hippocampal neurogenesis for the treatment of neurological and psychiatric disease using human neural stem cell technology. Read More
About India Globalization Capital Inc.
India Globalization Capital, Inc. (”IGC”) has developed a patent-pending cannabis-based combination therapy to treat endpoints of Alzheimer’s including plaques, tangles, anxiety, agitation and other NPS, which it plans to market through Canadian and U.S. medical dispensaries in early 2018. Its pipeline includes cannabis-based medications for end points of Parkinson’s, pain, nausea, eating disorders and epilepsy in cats and dogs. The company is also working on leveraging its expertise to develop blockchain technology based solutions for the cannabis market. IGC has a legacy business based in India, through which it is engaged in infrastructure and commodity trading, and in Malaysia it is engaged in real-estate management. IGC’s registered US office is located in Bethesda, Maryland. The company maintains an R&D center in Washington State and also has a back office in Kochi, Kerala India.
IGC announces intention to develop blockchain solution for cannabis market
On December 26, 2017, IGC announced that it plans to utilize blockchain technology to address industry issues specific to the medical cannabis industry. The company cited areas including product identification assurance (PIA), inadequate product labeling, transactional difficulties, and product origin assurance as areas that it was seeking to address. Clearly, blockchain technology, which uses a continuously growing list of records, called blocks, which are linked and secured using cryptography to manage large databases securely, is an area of high attention given its robust growth and crucial role in cryptocurrencies. We believe the company intends to develop a platform first for Hyaolex’s go-to-market strategy in the dispensary market, with an aim to leverage the platform for the highly regulated and rapidly evolving cannabis industry.
Alzheimer’s Disease (AD) is a form of dementia. It is known as America’s most expensive disease, with an estimated cost to the U.S. economy of $236 billion. AD currently affects more than 5.3 million Americans and over 65% of AD patients are women. Over the next 20 years, the number of those afflicted with the disease is expected to double. The forecast is staggering, considering that to date, no effective cure has been found.
Know more about India Globalization Capital Inc.
The Company has two lines of businesses, a legacy infrastructure business and a cannabis pharmaceutical business that has developed a lead product for treating Alzheimer’s patients. The company is based in Maryland, USA.